Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Gilead signs generic licensing deals for experimental Ebola drug

A late-stage trial is testing the drug in people at high risk after exposure. The deals are intended to line up manufacturing and supply before trial results and regulatory filings

Gilead signs generic licensing deals for experimental Ebola drug

Gilead Sciences recently announced agreements with three generic drug manufacturers to produce its experimental Ebola prevention drug, obeldesivir. This move aims to make the drug available in 127 low- and lower-middle-income countries, particularly those affected by the current Ebola Bundibugyo outbreak. The deals, which are royalty-free, include all African countries reporting Ebola cases.

Obeldesivir has shown preclinical activity against several Ebola-related viruses but is not yet approved for any use. A late-stage trial is currently testing the drug in individuals at high risk of exposure. Gilead is also expanding remdesivir licenses, potentially covering Ebola-related diseases, if trial results and regulatory approvals prove positive.

The company has donated over 38,000 vials of remdesivir to the Democratic Republic of Congo, Uganda, and Kenya, including a recent shipment to Kenya for investigational treatment and post-exposure prevention.

Written by urgent.news from The Hindu Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at thehindu.com →

More in Health & Medicine

More from Wednesday 18 November →